Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Will Sanofi Overpay For Actelion Innovation Or, Like J&J, Also Walk Away?

Executive Summary

Reported M&A talks between Sanofi and Actelion will likely stand or fall on the former's willingness to overpay and the target's demanded price for surrendering its independence.

Advertisement

Related Content

J&J’s $30bn For Actelion Buys Immediate And Longer-Term Value
J&J's Actelion Courtship Seen Unaffected By Macitentan MAESTRO Failure
Was Sanofi’s Offer One That Actelion Could Refuse? J&J Back At Bargaining Table
Actelion's Opsumit Shows MERIT In CTEPH
Sanofi CEO Upbeat Despite Medivation M&A Miss, Sarilumab Diss
Pfizer’s $14bn Medivation Buyout Shows How Far Pharma Will Go In Oncology

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097862

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel